Wall Street analysts expect AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) to report $167.23 million in sales for the current quarter, Zacks reports. Five analysts have provided estimates for AMAG Pharmaceuticals’ earnings. The lowest sales estimate is $161.86 million and the highest is $172.58 million. AMAG Pharmaceuticals reported sales of $143.78 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 16.3%. The firm is scheduled to issue its next quarterly earnings results on Thursday, November 2nd.

According to Zacks, analysts expect that AMAG Pharmaceuticals will report full year sales of $167.23 million for the current financial year, with estimates ranging from $638.99 million to $661.00 million. For the next year, analysts anticipate that the business will post sales of $546.78 million per share, with estimates ranging from $481.01 million to $584.07 million. Zacks’ sales calculations are an average based on a survey of analysts that follow AMAG Pharmaceuticals.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative return on equity of 4.81% and a negative net margin of 7.58%. The firm had revenue of $158.39 million during the quarter, compared to analyst estimates of $158.83 million. During the same period last year, the company earned $1.45 earnings per share. The business’s revenue for the quarter was up 24.3% on a year-over-year basis.

Several brokerages recently weighed in on AMAG. Morgan Stanley began coverage on shares of AMAG Pharmaceuticals in a report on Friday, September 8th. They issued an “overweight” rating and a $26.00 target price for the company. Deutsche Bank AG reaffirmed a “hold” rating and issued a $24.00 target price on shares of AMAG Pharmaceuticals in a report on Thursday, August 31st. BidaskClub downgraded shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Cowen and Company reaffirmed a “hold” rating on shares of AMAG Pharmaceuticals in a report on Thursday, August 10th. Finally, Zacks Investment Research downgraded shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 26th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and three have issued a buy rating to the stock. AMAG Pharmaceuticals currently has an average rating of “Hold” and an average price target of $27.92.

In related news, SVP Julie Krop sold 4,938 shares of the stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $20.00, for a total value of $98,760.00. Following the sale, the senior vice president now directly owns 28,336 shares of the company’s stock, valued at approximately $566,720. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 3.80% of the stock is currently owned by corporate insiders.

Institutional investors have recently bought and sold shares of the stock. Hikari Power Ltd raised its position in AMAG Pharmaceuticals by 75.0% in the 2nd quarter. Hikari Power Ltd now owns 70,000 shares of the specialty pharmaceutical company’s stock worth $1,288,000 after purchasing an additional 30,000 shares during the period. ClariVest Asset Management LLC raised its position in AMAG Pharmaceuticals by 23.9% in the 1st quarter. ClariVest Asset Management LLC now owns 36,800 shares of the specialty pharmaceutical company’s stock worth $830,000 after purchasing an additional 7,100 shares during the period. Vanguard Group Inc. raised its position in AMAG Pharmaceuticals by 6.1% in the 1st quarter. Vanguard Group Inc. now owns 3,085,348 shares of the specialty pharmaceutical company’s stock worth $69,576,000 after purchasing an additional 176,832 shares during the period. Legal & General Group Plc raised its position in AMAG Pharmaceuticals by 1.3% in the 1st quarter. Legal & General Group Plc now owns 61,371 shares of the specialty pharmaceutical company’s stock worth $1,384,000 after purchasing an additional 770 shares during the period. Finally, Sei Investments Co. raised its position in AMAG Pharmaceuticals by 0.7% in the 1st quarter. Sei Investments Co. now owns 8,342 shares of the specialty pharmaceutical company’s stock worth $188,000 after purchasing an additional 54 shares during the period.

AMAG Pharmaceuticals (NASDAQ:AMAG) traded down 3.91% during midday trading on Friday, reaching $19.65. The company had a trading volume of 1,874,354 shares. AMAG Pharmaceuticals has a 52 week low of $16.00 and a 52 week high of $36.83. The company’s market capitalization is $693.41 million. The firm has a 50-day moving average price of $18.20 and a 200-day moving average price of $19.90.

TRADEMARK VIOLATION WARNING: “Zacks: Brokerages Anticipate AMAG Pharmaceuticals, Inc. (AMAG) Will Post Quarterly Sales of $167.23 Million” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/09/17/zacks-brokerages-anticipate-amag-pharmaceuticals-inc-amag-will-post-quarterly-sales-of-167-23-million.html.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Get a free copy of the Zacks research report on AMAG Pharmaceuticals (AMAG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.